Lower Back and Sciatica Pain
Spinal Cord Stimulator Study
Purpose
To identify factors that predict the strongest responses to the treatment of spinal cord stimualtors.
Basic Eligibility Criteria
- Currently undergoing spinal cord stimulator treatment with UF Health Pain Medicine
- 45 to 85 years old
- Free from serious medical conditions
Study Site Location
UF Health Springhill
Contact
Email the Anesthesiology Research Operations team
SI Stem Cell Injection
A phase 1, open label dose-ranging study to assess the safety, tolerability, preliminary efficacy, and dose effect of CFL001 cord blood product in patients with symptomatic sacroiliac joint syndrome.
Purpose
The overall objective is to evaluate the safety and potential efficacy effect of specific type of umbilical cord blood product (CFL001).
Basic Eligibility Criteria
- 18 to 90 years old
- SI joint syndrome
- Have tried and failed other conservative pain therapies (i.e. Tylenol, NSAIDs, Tramadol, etc.)
Study Site Location(s)
Springhill 2 and Ayers
Contact
Email the Anesthesiology Research Operations team
Anticoagulant Reversal
Takeda TAK330-3001
A Phase 3, Prospective, Randomized, Open-label, Adaptive Group Sequential, Multicenter Trial with Blinded Endpoint Assessment to Evaluate the Efficacy and Safety of TAK-330 for the Reversal of Direct Oral Factor Xa Inhibitor-induced Anticoagulation in Patients Requiring Urgent Surgery/Invasive Procedure
Purpose
To compare the efficacy of TAK-330 to 4F-PCC used as a part of SOC for the reversal of direct oral Factor Xa inhibitor-induced anticoagulation in patients requiring urgent surgery/invasive procedure.
Basic Inclusion
- 18 years of age and older
- has taken an Anti-Xa medication (Eliquis (Apixaban), Xarelto (Rivaroxaban) or Savaysa (Edoxaban)) in the last 15 hours, or at any time beyond that if plasma anti-Fxa levels are elevated
- in need of urgent/emergent surgery (excluding cardiac catheterization, endoscopy, minor procedures)Study site location:
Study Site Locations
STH & HVN
Contact